<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517214</url>
  </required_header>
  <id_info>
    <org_study_id>TRANSFORM</org_study_id>
    <nct_id>NCT04517214</nct_id>
  </id_info>
  <brief_title>Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>Phase II Study of Comparing Toripalimab Combined With GP Regimen Chemotherapy Versus GP Regimen Chemotherapy for Primary Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University Eye and ENT Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hangzhou Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Medical Center Lihuili Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Changzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Chinese Academy of Medical Science, Shenzhen Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xi'anJiaotong Univerisity</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Panyu Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy of Toripalimab Combined with GP Regimen&#xD;
      Chemotherapy Versus GP Regimen Chemotherapy for Primary Metastatic NPC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 4-10% of patients with nasopharyngeal carcinoma (NPC) have metastatic disease at&#xD;
      diagnosis. The treatment recommendation of primary metastatic NPC is systemic chemotherapy.&#xD;
      However, the optimal regimen is yet to determine due to lack of prospective randomized trial&#xD;
      for this unique group of patients. Generally, GP regimen is used as the first-line treatment&#xD;
      of primary metastatic NPC. The aim of this study is to compare the efficacy of Toripalimab&#xD;
      Combined with GP Regimen Chemotherapy Versus GP Regimen Chemotherapy for Primary Metastatic&#xD;
      NPC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate of Systemic chemotherapy</measure>
    <time_frame>At the end of Cycle 6 of chemotherapy (each cycle is 21days)</time_frame>
    <description>ORR according to RECIST 1.1 Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate of Systemic chemotherapy</measure>
    <time_frame>At the end of Cycle 6 of chemotherapy (each cycle is 21days)</time_frame>
    <description>DCR according to RECIST 1.1 Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients received radiotherapy to nasopharynx</measure>
    <time_frame>2 year</time_frame>
    <description>Only patients with disease control after systemic chemotherapy will receive radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>5 year</time_frame>
    <description>Defined from date of randomization to date of first documentation of progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 year</time_frame>
    <description>Defined from date of randomization to date of first documentation of death from Defined from date of randomization to date of first documentation of death from any cause or censored at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Rate</measure>
    <time_frame>1 year, 2 year rates</time_frame>
    <description>Defined from date of randomization to date of first documentation of progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>1 year, 2 year rates</time_frame>
    <description>Defined from date of randomization to date of first documentation of death from Defined from date of randomization to date of first documentation of death from any cause or censored at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Incidence of Adverse Effect</measure>
    <time_frame>1 year</time_frame>
    <description>According to CTCAE 4.0.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Quality of life, according to EORTC QLQ-C30</measure>
    <time_frame>1 year</time_frame>
    <description>According to EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Quality of life, according to EORTC QLQ-H&amp;N35</measure>
    <time_frame>1 year</time_frame>
    <description>According to EORTC QLQ-H&amp;N35</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Toripalimab Combined with GP Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systemic chemotherapy for 6 cycles: Toripalimab 240mg d1+Gemcitabine 1.0g/m2 d1, Cisplatin 80mg/m2 d1, q3w; Followed by Radiotherapy to the nasopharynx and neck; Then maintenance therapy of Toripalimab with Capecitabine: Toripalimab 240mg d1+Capecitabine 1000mg/m2 bid d1-14, q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Systemic chemotherapy for 6 cycles: Gemcitabine 1.0g/m2 d1, Cisplatin 80mg/m2 d1, q3w; Followed by Radiotherapy to the nasopharynx and neck; Then maintenance therapy of Capecitabine: Capecitabine 1000mg/m2 bid d1-14, q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>PD-1 inhibitor</description>
    <arm_group_label>Toripalimab Combined with GP Arm</arm_group_label>
    <other_name>JS001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT to the nasopharynx and neck</intervention_name>
    <description>IMRT to the nasopharynx and neck</description>
    <arm_group_label>GP Arm</arm_group_label>
    <arm_group_label>Toripalimab Combined with GP Arm</arm_group_label>
    <other_name>RT to the nasopharynx and neck</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine and Cisplatin Chemotherapy</intervention_name>
    <description>Systemic chemotherapy</description>
    <arm_group_label>GP Arm</arm_group_label>
    <arm_group_label>Toripalimab Combined with GP Arm</arm_group_label>
    <other_name>GP regimen chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant chemotherapy with Capecitabine</intervention_name>
    <description>Adjuvant chemotherapy after radiation</description>
    <arm_group_label>GP Arm</arm_group_label>
    <arm_group_label>Toripalimab Combined with GP Arm</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign an informed consent;&#xD;
&#xD;
          2. Age older than 18 years old and younger than 70 years old;&#xD;
&#xD;
          3. Patients with newly histologically confirmed primary metastatic nasopharyngeal&#xD;
             carcinoma;&#xD;
&#xD;
          4. At least one metastatic site that fulfills the criteria of &quot;Evaluable Disease&quot; per&#xD;
             RECIST 1.1 Criteria;&#xD;
&#xD;
          5. Anticipated overall survival more than 3 months;&#xD;
&#xD;
          6. Satisfactory performance status: ECOG (Eastern Cooperative Oncology Group) scale 0-1;&#xD;
&#xD;
          7. No primary treatment of radiation, surgery, chemotherapy, targeted therapy and immune&#xD;
             therapy post diagnosis of NPC;&#xD;
&#xD;
          8. Neutrophil ≥ 1.5×109 /L and PLT ≥100×109 /L and HGB ≥90 g/L;&#xD;
&#xD;
          9. With normal liver function test (ALT、AST ≤ 3×ULN, TBIL≤ 1.5×ULN, Albumin≥2.8g/dL );&#xD;
&#xD;
         10. With normal renal function test (Creatinine ≤ 1.5 ×ULN and creatinine clearance ≥60&#xD;
             ml/min);&#xD;
&#xD;
         11. HBV DNA&lt;500 IU/mL（or 2500 copies/mL）and HCV RNA negative ;&#xD;
&#xD;
         12. Male and no pregnant female, able to adapt birth control methods during treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to Toripalimab, Gemcitabine, Cisplatin and Capecitabine;&#xD;
&#xD;
          2. Symptomatic spinal cord compression, or high-risk to develop pathological fracture&#xD;
             that requires urgent surgery or radiation;&#xD;
&#xD;
          3. Necrotic disease, high-risk of massive nasal bleeding;&#xD;
&#xD;
          4. Suffered from malignant tumors, except cervical carcinoma in situ, papillary thyroid&#xD;
             carcinoma, or skin cancer (non- melanoma) within five years;&#xD;
&#xD;
          5. Receive vaccine or live vaccine within 30 days prior to signing the informed consent;&#xD;
&#xD;
          6. Equivalent dose more than prednisone 10mg/d or other immunosuppressive treatments&#xD;
             within 28 days prior to signing the informed consent;&#xD;
&#xD;
          7. Severe, uncontrolled medical conditions and infections;&#xD;
&#xD;
          8. Active, known or suspected autoimmune disease; Type I Diabetes, hypothyroidism those&#xD;
             only need hormone replacement therapy; vitiligo or inactive asthma who don't need&#xD;
             systemic therapy can recruit;&#xD;
&#xD;
          9. History of interstitial lung disease;&#xD;
&#xD;
         10. HIV positive;&#xD;
&#xD;
         11. Hepatitis B surface antigen (HBsAg) positive and HBV-DNA ≥500IU/ml, or 2500cps/ml;&#xD;
             Positive HCV RNA;&#xD;
&#xD;
         12. Other diseases which may influence the safety or compliance of the clinical trial,&#xD;
             such as heart failure with symptom, unstable angina, myocardial infarction, active&#xD;
             infections those need systemic therapy, mental illness, or their family and society&#xD;
             factors;&#xD;
&#xD;
         13. Women of child-bearing potential who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaosu Hu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chaosu Hu, M.D.</last_name>
    <phone>+8621-64175590</phone>
    <phone_ext>81400</phone_ext>
    <email>hucsu62@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaomin Ou, M.D.</last_name>
    <phone>+8621-18017317872</phone>
    <email>0456218@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xiaomin Ou</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaomin Ou, M.D.</last_name>
      <phone>+8621-64175590</phone>
      <phone_ext>81400</phone_ext>
      <email>0456218@fudan.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Chaosu Hu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Jiang F, Jin T, Feng XL, Jin QF, Chen XZ. Long-term outcomes and failure patterns of patients with nasopharyngeal carcinoma staged by magnetic resonance imaging in intensity-modulated radiotherapy era: The Zhejiang Cancer Hospital's experience. J Cancer Res Ther. 2015 Oct;11 Suppl 2:C179-84. doi: 10.4103/0973-1482.168181.</citation>
    <PMID>26506872</PMID>
  </reference>
  <reference>
    <citation>Ou X, Zhou X, Shi Q, Xing X, Yang Y, Xu T, Shen C, Wang X, He X, Kong L, Ying H, Hu C. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost. Oncotarget. 2015 Nov 10;6(35):38381-97. doi: 10.18632/oncotarget.5420.</citation>
    <PMID>26485757</PMID>
  </reference>
  <reference>
    <citation>Lee AW, Ng WT, Chan LL, Hung WM, Chan CC, Sze HC, Chan OS, Chang AT, Yeung RM. Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era. Radiother Oncol. 2014 Mar;110(3):377-84. doi: 10.1016/j.radonc.2014.02.003. Epub 2014 Mar 11. Review.</citation>
    <PMID>24630534</PMID>
  </reference>
  <reference>
    <citation>Lang J, Gao L, Guo Y, Zhao C, Zhang C; Society of Head &amp; Neck Tumor Surgery; Society of Radiation Therapy; Chinese Anti-Cancer Association. Comprehensive treatment of squamous cell cancer of head and neck: Chinese expert consensus 2013. Future Oncol. 2014;10(9):1635-48. doi: 10.2217/fon.14.44. Epub 2014 Mar 17.</citation>
    <PMID>24635574</PMID>
  </reference>
  <reference>
    <citation>Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016 Mar 5;387(10022):1012-1024. doi: 10.1016/S0140-6736(15)00055-0. Epub 2015 Aug 28. Review.</citation>
    <PMID>26321262</PMID>
  </reference>
  <reference>
    <citation>Zou X, You R, Liu H, He YX, Xie GF, Xie ZH, Li JB, Jiang R, Liu LZ, Li L, Zhang MX, Liu YP, Hua YJ, Guo L, Qian CN, Mai HQ, Chen DP, Luo Y, Shen LF, Hong MH, Chen MY. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. Eur J Cancer. 2017 May;77:117-126. doi: 10.1016/j.ejca.2017.02.029. Epub 2017 Apr 7.</citation>
    <PMID>28391025</PMID>
  </reference>
  <reference>
    <citation>Sun XS, Liu LT, Liu SL, Guo SS, Wen YF, Xie HJ, Tang QN, Liang YJ, Li XY, Yan JJ, Ma J, Chen QY, Tang LQ, Mai HQ. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy. BMC Cancer. 2019 Jan 21;19(1):92. doi: 10.1186/s12885-019-5281-5.</citation>
    <PMID>30665378</PMID>
  </reference>
  <reference>
    <citation>Chua DT, Sham JS, Au GK. A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2005 Jul;41(6):589-95. Epub 2005 Apr 14. Review.</citation>
    <PMID>15975521</PMID>
  </reference>
  <reference>
    <citation>Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, Peng P, Wu X, Lin Q, Xi X, Peng J, Xu M, Chen D, Lu X, Wang R, Cao X, Chen X, Lin Z, Xiong J, Lin Q, Xie C, Li Z, Pan J, Li J, Wu S, Lian Y, Yang Q, Zhao C. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016 Oct 15;388(10054):1883-1892. doi: 10.1016/S0140-6736(16)31388-5. Epub 2016 Aug 23. Erratum in: Lancet. 2016 Oct 15;388(10054):1882.</citation>
    <PMID>27567279</PMID>
  </reference>
  <reference>
    <citation>Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, Zhang Y, Chen L, Zhou N, Zhao Y, Hou X, Yang Q, Zhang L. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018 Oct;19(10):1338-1350. doi: 10.1016/S1470-2045(18)30495-9. Epub 2018 Sep 10.</citation>
    <PMID>30213452</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>July 25, 2021</last_update_submitted>
  <last_update_submitted_qc>July 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chaosu Hu</investigator_full_name>
    <investigator_title>Vice Director of Department of Radiation Oncology, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>Primary metastatic</keyword>
  <keyword>de novo metastatic</keyword>
  <keyword>Toripalimab</keyword>
  <keyword>PD-1</keyword>
  <keyword>Immune checkpoint inhibitor</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

